Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 1.387
Filtrar
2.
Arch. bronconeumol. (Ed. impr.) ; 60(3): 143-152, Mar. 2024. ilus, mapas, tab
Artigo em Inglês | IBECS | ID: ibc-231098

RESUMO

Introduction: Although older adults represent a significant proportion of patients with venous thromboembolism (VTE), the data on the impact of age-related differences in the clinical presentation, management, and outcomes of VTE are scarce. Methods: We analyzed data from the RIETE registry database, an ongoing global observational registry of patients with objectively confirmed VTE, to compare patient characteristics, clinical presentation, treatments, and outcomes between elderly (≥70 years) vs. non-elderly (<70 years) patients. Results: From January 2001 to March 2021, 100,000 adult patients were enrolled in RIETE. Elderly patients (47.9%) were more frequently women (58.2% vs. 43.5%), more likely had unprovoked VTE (50.5% vs. 45.1%) and most often presented with severe renal failure (10.2% vs. 1.2%) and acute pulmonary embolism (PE) (vs. deep vein thrombosis) (54.3% vs. 44.5%) compared to non-elderly patients (p<0.001 for all comparisons). For the PE subgroup, elderly patients more frequently had non-low risk PE (78.9% vs. 50.7%; p<0.001), respiratory failure (33.9% vs. 21.8%; p<0.001) and myocardial injury (40.0% vs. 26.2%; p<0.001) compared to non-elderly patients. Thrombolysis (0.9% vs. 1.7%; p<0.001) and direct oral anticoagulants (8.8% vs. 11.8%; p<0.001) were less frequently administered to elderly patients. Elderly patients showed a significantly higher 30-day all-cause mortality (adjusted odds ratio [OR] 1.36, 95%CI: 1.22–1.52) and major bleeding (OR, 2.08; 95%CI, 1.85–2.33), but a lower risk of 30-day VTE recurrences (OR, 0.62, 95%CI, 0.54–0.71). Conclusions: Compared with non-elderly patients, elderly patients had a different VTE clinical profile. Advanced therapies were less frequently used in older patients. Age was an independent predictor of mortality.(AU)


Assuntos
Humanos , Masculino , Feminino , Pessoa de Meia-Idade , Idoso , Tromboembolia Venosa/diagnóstico , Tromboembolia Venosa/mortalidade , Recidiva , Hemorragia , Anticoagulantes , Embolia Pulmonar
4.
Rev. esp. enferm. dig ; 115(12): 682-685, Dic. 2023. ilus
Artigo em Inglês, Espanhol | IBECS | ID: ibc-228702

RESUMO

La trombosis venosa portal es una complicación infrecuente de los pacientes con cirrosis, que habitualmente aparece en las fases más avanzadas de la enfermedad. Aunque no disponemos de una evidencia sólida, la anticoagulación está indicada en algunos grupos de pacientes en los que la gravedad de la oclusión portal o en los que su especial situación de cara al trasplante requiere intentar la recanalización portal. Más allá de la recanalización, la anticoagulación parece tener un efecto beneficioso en la historia natural de la cirrosis, lo que plantea dudas sobre la oportunidad de su retirada una vez iniciada.(AU)


Assuntos
Humanos , Masculino , Feminino , Cirrose Hepática/complicações , Trombose Venosa/tratamento farmacológico , Hipertensão Portal , Anticoagulantes/administração & dosagem , Trombose Venosa/complicações , Fatores de Risco , Doenças do Sistema Digestório
6.
Gastroenterol. hepatol. (Ed. impr.) ; 46(8): 621-627, oct. 2023. tab, ilus
Artigo em Inglês | IBECS | ID: ibc-225940

RESUMO

Background: Oral anticoagulation in non-valvular atrial fibrillation is associated with an increased risk of bleeding, particularly gastrointestinal bleeding, leading to treatment withdrawal in up to 50% of patients and putting them at risk of embolic events. Left atrial appendage closure (LAAC) can be an alternative to chronic anticoagulation. We aim to describe the impact of LAAC in patients with gastrointestinal bleeding (GIB) or chronic iron deficiency anaemia (CIDA) on healthcare resources consumption. Methods: Observational retrospective study of patients who underwent LAAC for GIB or CIDA at a single centre. Results: Nineteen patients with a median age of 74 years and a median Charlson score of six points were included in the study. Angiodysplasias were the most frequent cause of GIB or CIDA. The procedural success rate of LAAC was 100% with a median anticoagulant and antiplatelet treatment duration of 92 days. One year after the LAAC, we found a significant improvement in the lowest haemoglobin concentration and a reduction in the number of red blood cells transfusion, hospital admissions due to GIB and CIDA and the number of endoscopic examinations. One patient died due to a pulmonary thromboembolism. No deaths related to GIB were observed. Conclusions: LAAC seems to be a safe and effective alternative to anticoagulation in patients with GIB or CIDA. (AU)


Introducción: La anticoagulación oral en la fibrilación auricular no valvular se asocia a un incremento del riesgo de sangrado, especialmente gastrointestinal, lo que conlleva la retirada del tratamiento hasta en el 50% de los pacientes e implica un mayor riesgo de padecer un evento embólico. El cierre de la orejuela izquierda (COI) puede ser una alternativa a la anticoagulación crónica. Nuestro objetivo es describir el impacto del COI en pacientes con sangrado gastrointestinal (SGI) o anemia crónica ferropénica (ACF) en el consumo de recursos sanitarios. Métodos: Estudio observacional retrospectivo de pacientes sometidos a COI por SGI o ACF. Resultados: Diecinueve pacientes con una mediana de edad de 74años y una mediana del índice de Charlson de 6puntos fueron incluidos en el estudio. Las angiodisplasias fueron la causa más frecuente de SGI o ACF. La tasa de éxito técnico del COI fue del 100%, con una duración mediana del tratamiento anticoagulante y antiagregante de 92días. Tras un año del COI, se observó una mejoría significativa del valor mínimo de hemoglobina, así como una reducción en el número de transfusiones de concentrados de hematíes, en la necesidad de hospitalización por SGI o ACF y en el número de endoscopias. Un paciente falleció debido a un tromboembolismo pulmonar. Ningún paciente falleció por SGI. Conclusiones: El COI parece una alternativa segura y efectiva a la anticoagulación en pacientes con SGI o ACF. (AU)


Assuntos
Humanos , Masculino , Feminino , Idoso , Idoso de 80 Anos ou mais , Fibrilação Atrial , Hemorragia Gastrointestinal , Anemia Ferropriva , Estudos Retrospectivos , Epidemiologia Descritiva , Anticoagulantes
8.
Rev. esp. cardiol. (Ed. impr.) ; 76(9): 690-699, Sept. 2023. ilus, graf, tab
Artigo em Espanhol | IBECS | ID: ibc-224453

RESUMO

Introducción y objetivos: Los anticoagulantes orales directos (ACOD) se han mostrado eficaces y seguros en pacientes con fibrilación auricular; sin embargo, los pacientes con FA y bioprótesis están infrarrepresentados en los ensayos clínicos, por lo que la evidencia en este grupo es menor. Nuestro objetivo fue analizar la seguridad y eficacia de los ACODs en esta población revisando la información existente en la literatura. Métodos: Se realizó una búsqueda y revisión sistemática con los ensayos clínicos aleatorizados y estudios observacionales comparativos desde 2017 a enero de 2022, que comparasen ACODs y antagonistas de vitamina K (AVK) en pacientes con FA y bioprótesis. Se utilizó la hazard ratio al 95% del intervalo de confianza para comparar ambos grupos en términos de mortalidad total y cardiovascular, ictus/embolia sistémica y hemorragia mayor. Se realizó un metanálisis combinando los resultados de los estudios incluidos. Resultados: Se incluyeron 12 estudios (un total de 30.283 pacientes). Los ACODs se asociaron a una reducción significativa del 9% de la mortalidad total (HR=0,91; IC95%, 0,85-0,97; p=0,0068; I2=8%), sin diferencias significativas en el riesgo de ictus/embolismo sistémico (HR=0,87; IC95%, 0,67-1,14; p=0,29; I2=45%) o hemorragia mayor (HR=0,82; IC95%, 0,67-1,00; p=0,054; I2=48.7%). Conclusiones: En pacientes con FA portadores de bioprótesis, los ACODs podrían asociarse a una reducción de la mortalidad total sin reducción de eficacia en la prevención de ictus/embolia sistémica o aumento del riesgo de hemorragia mayor.(AU)


Introduction and objectives: Direct oral anticoagulant (DOAC) therapy has been shown to be safe and effective in patients with atrial fibrillation (AF). However, outcomes in AF patients with bioprosthetic valves are unclear, as this population has been underrepresented in clinical trials. The aim of this study was to assess the safety and efficacy of DOACs in this population based on the existing published literature. Methods: A systematic search and review were conducted to identify randomized clinical trials and comparative observational studies published from 2017 to January 2022 that compared DOACs and vitamin K antagonists (VKAs) in AF patients with bioprosthetic valves. Hazard ratios (HR) were collected to compare the 2 treatments in terms of cardiovascular and all-cause mortality, stroke/systemic embolism, and major bleeding. A meta-analysis combining the results was performed. Results: We included 12 studies (30 283 patients). DOACs and VKAs were compared based on HRs at the 95% confidence interval. DOAC therapy was associated with a significant 9% reduction in all-cause mortality (HR, 0.91; 95%CI, 0.85-0.97; P=.0068; I2=8%), with no significant differences in the risk of stroke/systemic embolism (HR, 0.87; 95%CI, 0.67-1.14; P=.29; I2=45%) or major bleeding (HR, 0.82; 95%CI, 0.67-1.00; P=.054; I2=48.7%). Conclusions: DOAC therapy in AF patients with bioprosthetic valves may be associated with a significant reduction in all-cause mortality, with no reduction in the efficacy of stroke/systemic embolism prevention or increase in major bleeding risk.(AU)


Assuntos
Humanos , Masculino , Feminino , Fibrilação Atrial , Bioprótese , Anticoagulantes , Cardiologia
9.
Rev. esp. cardiol. (Ed. impr.) ; 76(9): 729-738, Sept. 2023. tab, graf
Artigo em Espanhol | IBECS | ID: ibc-224457

RESUMO

Introducción y objetivos: Existe escasa evidencia acerca del impacto de las actuales recomendaciones sobre la utilización del tratamiento antitrombótico durante el periodo perioperatorio y periprocedimiento en el «mundo real». El objetivo de este estudio es analizar la utilización de los fármacos antitrombóticos en una población de pacientes que van a someterse a una cirugía/procedimiento, así como evaluar la implicación que tiene su retirada o mantenimiento en la incidencia de eventos adversos trombóticos y/o hemorrágicos. Métodos: Estudio observacional prospectivo, multicéntrico y multiespecialidad de pacientes en tratamiento antitrombótico que precisen alguna intervención. El objetivo principal fue la incidencia de eventos trombóticos y hemorrágicos a 30 días en función del uso periintervención de los fármacos antitrombóticos. Resultados: Se incluyó a un total de 1.266 pacientes (el 63,5% varones; media de edad, 72,6 años). El 48,6% de ellos se encontraban anticoagulados (la mayoría por fibrilación auricular; CHA2DS2-VASC, 3,7) y el 53,3%, antiagregados, con mayor frecuencia por cardiopatía isquémica. El 66,7% tenía un riesgo isquémico bajo y el 51,9%, un riesgo hemorrágico de la intervención bajo. El tratamiento antitrombótico periprocedimiento según las recomendaciones actuales fue idóneo únicamente en el 57,3% de los casos. Los pacientes con un uso inadecuado de los fármacos antitrombóticos periprocedimiento presentaron una incidencia de eventos adversos trombóticos y hemorrágicos significativamente mayor. Conclusiones: A pesar de las recomendaciones actuales acerca de la utilización de fármacos antitrombóticos en el periodo perioperatorio/periprocedimiento, su implementación en el «mundo real» continúa siendo baja. Un uso inadecuado se asocia con un aumento de la incidencia de eventos adversos, tanto trombóticos como hemorrágicos.(AU)


Introduction and objectives: There is scarce real-world evidence on the management of perioperative antithrombotic treatment according to current recommendations. The aim of this study was to analyze the management of antithrombotic treatment in patients undergoing surgery or another invasive intervention and to assess the consequences of this management on the occurrence thrombotic or bleeding events. Methods: This prospective, observational, multicenter and multispecialty study analyzed patients receiving antithrombotic therapy who underwent surgery or another invasive intervention. The primary endpoint was defined as the incidence of adverse (thrombotic and/or hemorrhagic) events after 30 days of follow-up with respect to management of perioperative antithrombotic drugs. Results: We included 1266 patients (male: 63.5%; mean age 72.6 years). Nearly half of the patients (48.6%) were under chronic anticoagulation therapy (mainly for atrial fibrillation; CHA2DS2-VASC: 3.7), while 53.3% of the patients were under chronic antiplatelet therapy (mainly for coronary artery disease). Low ischemic and hemorrhagic risk was found in 66.7% and 51.9%, respectively. Antithrombotic therapy management was in line with current recommendations in only 57.3% of the patients. Inappropriate management of antithrombotic therapy was an independent risk factor for both thrombotic and hemorrhagic events. Conclusions: The implementation of recommendations on the perioperative/periprocedural management of antithrombotic therapy in real-world patients is poor. Inappropriate management of antithrombotic treatment is associated with an increase in both thrombotic and hemorrhagic events.(AU)


Assuntos
Humanos , Masculino , Feminino , Idoso , Período Perioperatório/métodos , Fibrinolíticos , Anticoagulantes , Cirurgia Geral , Tratamento Farmacológico , Estudos Prospectivos , Cardiologia , Cardiopatias
10.
Acta otorrinolaringol. esp ; 74(4): 243-252, Julio - Agosto 2023. tab
Artigo em Inglês | IBECS | ID: ibc-223484

RESUMO

Background This study aimed to analyze the behavior of acute invasive fungal rhinosinusitis (AIFRS) associated with COVID-19 infection as there has been an increase in the rate of AIFRS cases in the last two years, and many reports connected this rising with the COVID-19 infection. We studied most factors that may impact the prognosis as a trial to find the most affecting factors to improve the outcomes. Methods It was a retrospective observational study that included cases from four tertiary referral institutions between November 2020 to February 2022. We included sixty-six patients who suffered from AIFRS associated with confirmed COVID-19. We observed the prognosis of all included patients with a six-month follow-up. We correlated the prognosis with many factors, such as demographic data, medical conditions, blood investigations, the features of fungal infections, and management. Results Forty-two patients (64%) survived after the AIFRS associated with COVID-19, and twenty-two patients (36%) died. High doses of corticosteroids with prolonged use were the main factors that affected the behavior of the AIFRS associated with COVID-19. HbA1c was a good predictor of the prognosis; a level less than 9.35% may indicate survival with 87.5% sensitivity. Conclusions According to this multi-center study, the mortality of the AIFRS associated with COVID-19 was high. The behavior was affected by glycemic control, the type of fungal species, and the type of antifungal therapy. Early surgical debridement, a combination of Amphotericin B with Voriconazole, and anticoagulants helped improve the prognosis. (AU)


Antecedentes Durante el periodo de la pandemia de COVID19, ha habido un aumento en la tasa de casos de rinosinusitis fúngica invasiva aguda (RSFIA), siendo cada vez más evidente la asociación entre ambas entidades. EL objetivo de este estudio ha sido analizar la evolución de los pacientes con rinosinusitis fúngica invasiva aguda asociado con la infección por COVID-19, analizando los factores determinantes en la evolución y pronóstico de la enfermedad. Métodos Fue un estudio observacional retrospectivo que incluyó casos de cuatro instituciones de referencia de tercer nivel entre noviembre de 2020 y febrero de 2022. Se incluyeron sesenta y seis pacientes que padecían RSFIA asociado a COVID-19 confirmado. Observamos el pronóstico de todos los pacientes incluidos con un seguimiento de seis meses. Correlacionamos el pronóstico con muchos factores, como los datos demográficos, las condiciones médicas, las investigaciones de sangre, las características de las infecciones fúngicas y el manejo. Resultados Cuarenta y dos pacientes (64%) sobrevivieron después de la RSFIA asociada a COVID-19, y veintidós pacientes (36%) fallecieron. Las dosis altas de corticoides con uso prolongado fueron los principales factores que afectaron el comportamiento de la RSFIA asociada a la COVID-19. HbA1c fue un buen predictor del pronóstico; un nivel inferior al 9,35 % puede indicar supervivencia con una sensibilidad del 87.5%. Conclusiones Según este estudio multicéntrico, la mortalidad de la RSFIA asociada a la COVID-19 fue alta. El comportamiento se vio afectado por el control glucémico, el tipo de especie fúngica y el tipo de terapia antifúngica. El desbridamiento quirúrgico temprano, una combinación de Amphotericin B con Voriconazole y anticoagulantes ayudaron a mejorar el pronóstico. (AU)


Assuntos
Humanos , Prognóstico , Corticosteroides , Anticoagulantes , Pandemias , Infecções por Coronavirus/epidemiologia
13.
Emergencias (Sant Vicenç dels Horts) ; 35(4): 252-260, ago. 2023. ilus, tab, graf
Artigo em Espanhol | IBECS | ID: ibc-223761

RESUMO

Objetivos: Analizar los beneficios y seguridad a largo plazo de la anticoagulación oral (ACO) prescrita en los servicios de urgencias (SU) a pacientes mayores con fibrilación auricular (FA) y las diferencias en función del sexo. Método: Se trata de un análisis post-hoc del estudio EMERG-AF. Se incluyeron pacientes consecutivos $ 75 años, que consultaron en 62 SU por FA. Se recogieron datos clínicos y ACO. La variable principal estuvo compuesta por muerte, tromboembolia o sangrado mayor en 1 año. Resultados: Se incluyeron 690 pacientes, 386 mujeres (55,9%). Al alta, 575 pacientes (83,3%) estaban con ACO. En 96 de ellos se inició en el SU. Tras 1 año, la variable principal sucedió en 158 pacientes (22,9%): 118 (17,1%) fallecieron, 22 (2,7%) tuvieron una complicación tromboembólica y 34 (4,9%) una hemorragia mayor. Tras ajustar por las principales características clínicas, la ACO se asoció a una reducción en la variable principal (HR: 0,372, IC 95%: 0,236-0,587, p < 0,001), pero no se asoció con la hemorragia mayor. En las mujeres, la ACO se asoció con una reducción en la variable principal (HR: 0,372, IC 95%: 0,236-0,587, p < 0,001) y una menor mortalidad (HR: 0,281, IC 95%: 0,168-0,469, p < 0,001), incluidos pacientes con nueva prescripción y en aquellos dados de alta. Esta asociación no alcanzó significación en los hombres. (AU)


Objectives: To analyze the long-term benefits and safety of oral anticoagulation therapy prescribed in emergency departments for elderly patients with atrial fibrillation, and to detect any sex-related differences present. Material and methods: Post-hoc analysis of data compiled by the EMERG-AF group (Spanish acronym for Emergency Department Stroke Prophylaxis and Guidelines Implementation in Atrial Fibrillation). Consecutive patients aged 75 years or older with atrial fibrillation who were treated in 62 EDs were included. We recorded clinical data and anticoagulants prescribed. Patients were followed for 1 year. The main outcome variable was a composite of death, thromboembolism, or major bleeding within 1 year. Results: Data for 690 patients were registered; 386 (55.9%) were women. At discharge, 575 patients (83.3%) were on anticoagulants; therapy was started in the ED for 96 of them. A total of 158 patients (22.9%) had experienced at least 1 component of the main outcome within 1 year: 118 (17.1%) died, 22 (2.7%) had thromboembolic complications, and 34 (4.9%) had major bleeding. After adjustment for main clinical characteristics, hazard ratios (HRs) showed that anticoagulation therapy was associated with a reduction in the composite outcome (HR, 0.372; 95% CI, 0.236-0.587; P .001) but not specifically with major bleeding overall. When data for women were analyzed separately, anticoagulant therapy was again associated with a reduction in the composite outcome (HR, 0.372; 95% CI, 0.236-0.587; P .001) and also with death (HR, 0.281; 95% CI, 0.168-0.469; P .001), even in patients with anticoagulant prescriptions initiated on discharge from the ED. These associations did not reach statistical significance in men. (AU)


Assuntos
Humanos , Masculino , Feminino , Idoso , Idoso de 80 Anos ou mais , Acidente Vascular Cerebral , Fibrilação Atrial/complicações , Fibrilação Atrial/diagnóstico , Fibrilação Atrial/tratamento farmacológico , Tromboembolia , Hemorragia/induzido quimicamente , Hemorragia/tratamento farmacológico , Anticoagulantes/uso terapêutico , Envelhecimento
15.
Rev. clín. esp. (Ed. impr.) ; 223(6): 340-349, jun.- jul. 2023.
Artigo em Espanhol | IBECS | ID: ibc-221349

RESUMO

Objetivos El objetivo consistía en evaluar un programa de gestión de anticoagulantes orales directos (ACOD) en pacientes con fibrilación auricular no valvular (FANV) según sus perfiles, idoneidad de la dosis, patrones de cambio de tratamiento, efectividad y seguridad Se trató de un estudio observacional, prospectivo y longitudinal en una cohorte de pacientes atendidos en la práctica clínica cotidiana en un hospital regional español con un plan de seguimiento de 3 años para pacientes que iniciaron el tratamiento con dabigatrán, rivaroxabán o apixabán entre enero de 2012 y diciembre de 2016. Métodos Se analizaron 490 episodios de tratamiento (apixabán 2,5mg, 9,4%; apixabán 5mg, 21,4%; dabigatrán 75mg, 0,6%; dabigatrán 110mg, 12,4%; dabigatrán 150mg, 19,8%; rivaroxabán 15mg, 17,8%; rivaroxabán 20mg, 18,6%) en 445 pacientes. En el 13,6% de los pacientes tratados con dabigatrán, el 9,7% de los tratados con rivaroxabán y el 3,9% de los tratados con apixabán se cambió a otros ACOD o se modificó la dosis. Resultados El ACOD al que se cambió con mayor frecuencia fue el apixabán. Los motivos más frecuentes para cambiar de tratamiento fueron toxicidad (23,8%), hemorragia (21,4%) y deterioro renal (16,7%). En el 23,8% de los episodios se constató una inadecuación de la dosis. Las tasas de ictus y accidentes isquémicos transitorios (AIT) fueron de 1,64 y 0,54 eventos/100 años/paciente, respectivamente, mientras que las de hemorragias importantes, no importantes, pero clínicamente relevantes (NICR) e intracraneales fueron de 2,4, 5 y 0,5 eventos/100 años/paciente, respectivamente. Las hemorragias digestivas y genitourinarias fueron el tipo más frecuente de eventos hemorrágicos. En el análisis multifactorial, el ictus previo y la edad fueron factores predictivos independientes de ictus/AIT. El uso concomitante de antiagregantes plaquetarios, el sexo masculino y la edad fueron factores predictivos independientes de eventos hemorrágicos (AU)


Aims The aim is to evaluate a management program for direct oral anticoagulants (DOACs) in non-valvular atrial fibrillation (NVAF) patients according to their profiles, appropriateness of dosing, patterns of crossover, effectiveness and safety. This is an observational and longitudinal prospective study in a cohort of patients attended in daily clinical practice in a regional hospital in Spain with 3-year a follow-up plan for patients initiating dabigatran, rivaroxaban or apixaban between Jan/2012 and Dec/2016. Methods We analyzed 490 episodes of treatment (apixaban 2.5, 9.4%; apixaban 5, 21.4%; dabigatran 75, 0.6%; dabigatran 110, 12.4%; dabigatran 150, 19.8%; rivaroxaban 15, 17.8% and rivaroxaban 20, 18.6%) in 445 patients. 13.6% of patients on dabigatran, 9.7% on rivaroxaban, and 3.9% on apixaban switched to other DOACs or changed dosing. Results Apixaban was the most frequent DOAC switched to. The most frequent reasons for switching were toxicity (23.8%), bleeding (21.4%) and renal deterioration (16.7%). Inappropriateness of dose was found in 23.8% of episodes. Rates of stroke/transient ischemic attack (TIA) were 1.64/0.54 events/100 patients-years, while rates of major, clinically relevant non-major (CRNM) bleeding and intracranial bleeding were 2.4, 5, and 0.5 events/100 patients-years. Gastrointestinal and genitourinary bleeding were the most common type of bleeding events (BE). On multivariable analysis, prior stroke and age were independent predictors of stroke/TIA. Concurrent platelet inhibitors, male gender and age were independent predictors of BE. Conclusion This study complements the scant data available on the use of DOACs in NVAF patients in Spain, confirming a good safety and effectiveness profil (AU)


Assuntos
Humanos , Masculino , Feminino , Idoso , Padrões de Prática Médica , Fibrilação Atrial/tratamento farmacológico , Anticoagulantes/administração & dosagem , Dabigatrana/administração & dosagem , Rivaroxabana/administração & dosagem , Seguimentos , Estudos Prospectivos , Estudos Longitudinais , Resultado do Tratamento , Administração Oral , Espanha
16.
Rev. int. med. cienc. act. fis. deporte ; 23(90): 135-146, jun. 2023. tab
Artigo em Inglês | IBECS | ID: ibc-222607

RESUMO

The interactions between hypoglycemic drugs and other drugs were retrieved based on the pharmacy information database to evaluate the X-level/contraindication and D-level/serious potential drug interactions (pDDIs) of outpatient anticoagulant prescriptions, so as to provide a guarantee for clinically safe drug use. METHODS: Based on the interaction of 5 oral anticoagulants recommended in the "China Guidelines for the Prevention and Treatment of Thrombotic Diseases (2018 Edition)" retrieved from the two databases of Lexicomp and Micromedex, statistics of a hospital from January 1,2021 to 2022 During March 31st,200 outpatients with anticoagulant prescriptions for grade X/contraindication and grade D/severe pDDIs were analyzed by multivariate Logistic binary regression analysis. RESULTS: Among the 200 athletic patients, there were 0 pairs of grade X/taboo pDDIs,and 67 pairs of grade D/severe pDDIs, mainly due to grade D/serious potential bleeding caused by the combination of anticoagulants and non-steroidal anti-inflammatory drugs(NSAIDs) risk. Multivariate Logistic binary regression analysis found that multiple drug combination (≥5 kinds) and concomitant cardiovascular disease were risk factors for the occurrence of grade D/severe pDDIs. CONCLUSION: for athletic patients with multiple diseases coexisting and needing to take multiple drugs, it is necessary to pay attention to the pDDIs of anticoagulant drugs, select appropriate drugs, and avoid fatal risks such as severe bleeding. Adverse reactions after medication were closely monitored. (AU)


Assuntos
Humanos , Masculino , Feminino , Adulto Jovem , Adulto , Pessoa de Meia-Idade , Idoso , Idoso de 80 Anos ou mais , Anticoagulantes/farmacologia , Anticoagulantes/uso terapêutico , Interações Medicamentosas , Bases de Dados como Assunto , Modelos Logísticos , Atletas
17.
Pharm. pract. (Granada, Internet) ; 21(2): 1-10, abr.-jun. 2023. ilus, tab
Artigo em Inglês | IBECS | ID: ibc-222801

RESUMO

Background: Recently, direct oral anticoagulant (DOAC) has been projected for secondary prevention of recurrent ischemic events post-acute coronary syndrome (ACS). The addition of a DOAC to the antiplatelet regimen of subjects with the ACS is clinically practiced in candidates where compelling anticoagulation is indicated by high thromboembolic risk. The current evidence provides approved compelling indication for the DOAC, particularly for rivaroxaban which bears the strongest existing evidence. Objective: We intend to assess the role of DOAC in addition to single or dual antiplatelet therapy in subjects with ACS. We will compare the clinical characteristics and explore the efficacy and safety of the DOAC class members (apixaban, betrixaban, dabigatran, edoxaban and rivaroxaban) in terms of reduction in ischemic events in subjects with ACS (ST-segment elevation myocardial infarction [STEMI] or non–ST-segment elevation [NSTEMI]) or subjects who underwent percutaneous coronary intervention (PCI) and or ACS and coexisting atrial fibrillation (AF). Methods: Relevant data will be searched on known data-bases such as Embase, Google Scholar, the Cochrane Central, and PubMed. The trials included will be randomized controlled trials from 2009 to 2022. Subjects will be receiving DOAC for ACS were evaluated for inclusion. The extraction, synthesis, quality, and validity of data will follow the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. The risk of bias tool, version 2.0 (Cochrane) will be used for risk of bias assessment. Data will be pooled using random-effects models. The primary outcome measure will be efficacy end point (composite of cardiovascular death, myocardial infarction, and stroke), while the safety outcome will be minor/major bleeding. (AU)


Assuntos
Humanos , Anticoagulantes , Síndrome Coronariana Aguda/prevenção & controle , Síndrome Coronariana Aguda/terapia , Ensaios Clínicos Controlados Aleatórios como Assunto , Fibrilação Atrial , Infarto do Miocárdio , Intervenção Coronária Percutânea
18.
Metas enferm ; 26(3): 15-22, Abr. 2023. tab
Artigo em Espanhol | IBECS | ID: ibc-218746

RESUMO

Objetivo: analizar el incremento de conocimientos y el grado de satisfacción obtenidos mediante una intervención educativa para las personas en tratamiento anticoagulante (TAO) seguidas en Atención Primaria. Método: estudio antes-después sin grupo control. La población fueron personas en TAO en seguimiento en el Área de Salud de Gran Canaria (40 centros de salud (CS); N= 11.808). Se estimó una muestra de 250 personas. Se realizó una sesión educativa teórica (40 min) y práctica (60 min) dirigida por una enfermera con grupos de ocho a 16 personas. Se midieron basalmente variables sociodemográficas, clínicas, de tratamiento, conocimientos en anticoagulación medidos con el cuestionario OAK (mín. 0 a máx. 20 puntos) y la satisfacción con la sesión. Se reevaluó el conocimiento a los cuatro meses. Se llevó a cabo estadística descriptiva y bivariante. Resultados: participaron 145 personas de 23 centros de salud (x= 66,9 años; 55,2% hombres). Hubo un aumento del porcentaje de respuestas acertadas y una disminución de las respuestas en blanco en todas las preguntas, siendo estadísticamente significativo el cambio en 16 de ellas (p< 0,05). La media de puntuación del cuestionario OAK aumentó de manera estadísticamente significativa [pretest (= 9,6); postest (=13,8);p= 0,000)]. Un 84,8% de los sujetos había mejorado sus conocimientos tras haber participado en la sesión. El 80% o más encontró muy adecuados distintos aspectos de la sesión. El 91% la recomendaría a otros pacientes. Conclusión: hubo un mayor nivel de conocimientos en anticoagulación a los cuatro meses de la participación en la sesión educativa grupal guiada por una enfermera.(AU)


Objective: to analyse the increase in knowledge and level of satisfaction achieved through an educational intervention for persons on anticoagulant therapy (OAT) followed up at Primary Care. Method: a before-and-after study without control arm. The population was formed by patients on OAT followed up at the Gran Canaria Health Area (40 primary care centres (PCCs); N=11,808). The sample was calculated at 250 persons. A theoretical education session (40 minutes), and a practical session (60 minutes) were led by a nurse with groups from eight to sixteen persons. The following variables were measured at baseline: sociodemographic, clinical, treatment-related, knowledge on anticoagulation measured with the OAK questionnaire (minimum score: 0, maximum score: 20 points), and satisfaction with the session. Knowledge was re-evaluated at four months. Descriptive and bivariate statistics was conducted. Results: the study included 145 persons from 23 PCCs (x= 66.9 years; 55.2% male). There was an increase in the proportion of correct answers and a reduction in blank answers for all questions; the change in 16 of them was statistically significant (p< 0.05). There was a statistically significant increase in the mean score for the OAK questionnaire [pre-test (= 9.6); post-test (=13.8); p= 0.000)]. In total, 845 of the subjects had improved their knowledge after their participation in the session; 80% or more found that different aspects of the session were very adequate, and 91% would recommend it to other patients. Conclusion: there was a higher level of knowledge regarding anticoagulation four months after participating in the group educational session led by a nurse.(AU)


Assuntos
Humanos , Masculino , Feminino , Pessoa de Meia-Idade , Idoso , Anticoagulantes , Conhecimento , Atenção Primária à Saúde , Educação em Saúde , Conhecimentos, Atitudes e Prática em Saúde , Enfermeiras e Enfermeiros , Inquéritos e Questionários , Cuidados de Enfermagem
19.
Radiología (Madr., Ed. impr.) ; 65(2): 176-179, mar.- abr. 2023. ilus
Artigo em Espanhol | IBECS | ID: ibc-217619

RESUMO

La enfermedad causada por SARS-CoV-2 (Covid-19) se ha convertido en una pandemia mundial y en consecuencia en un problema de salud pública. Se han descrito múltiples complicaciones asociadas a la COVID-19, entre ellas alteraciones de la coagulación. Si bien es conocido que la infección induce un estado protrombótico, también se han descrito complicaciones hemorrágicas en estos pacientes, sobre todo en pacientes anticoagulados. Presentamos dos casos de hematoma pulmonar espontáneo en pacientes con neumonía COVID-19 y terapia anticoagulante. Nuestro objetivo es describir esta complicación, que, aunque poco frecuente, conviene tener en cuenta en pacientes anticoagulados y con COVID-19 concomitante (AU)


The disease caused by Sars-Cov-2 (Covid-19) has become a worldwide pandemic and consequently a public health problem. Multiple complications associated with Covid-19 have been described, including coagulation abnormalities. Although the infection is known to induce a prothrombotic state, hemorrhagic complications have also been reported in patients with Covid-19, especially in anticoagulated patients. We present two cases of spontaneous pulmonary hematoma in patients with Covid-19 undergoing anticoagulant treatment. We aim to describe this complication, which although uncommon, should be taken into account in anticoagulated patients with Covid-19 (AU)


Assuntos
Humanos , Masculino , Idoso , Infecções por Coronavirus/complicações , Pneumonia Viral/complicações , Pandemias , Hematoma/diagnóstico por imagem , Hematoma/etiologia , Anticoagulantes/efeitos adversos , Pneumopatias/diagnóstico por imagem , Pneumopatias/etnologia , Tomografia Computadorizada por Raios X
20.
Med. clín (Ed. impr.) ; 160(9): 400-406, 12 may 2023. ilus
Artigo em Inglês | IBECS | ID: ibc-220473

RESUMO

La trombosis venosa mesentérica (TVM) es una entidad poco frecuente que puede presentarse de manera aguda, subaguda o crónica. Puede ocurrir de forma aislada o en el seno de una trombosis esplácnica (espleno-porto-mesentérica). Los casos sintomáticos suelen presentarse como dolor abdominal inespecífico, con o sin datos de sufrimiento intestinal, y el diagnóstico se realiza habitualmente mediante una prueba de imagen (TC abdominal o RMN) en pacientes con una alta sospecha clínica. Se recomienda un enfoque clínico-quirúrgico precoz para cribar aquellos pacientes con datos de alarma y que se beneficien de una laparotomía exploradora añadida al tratamiento anticoagulante, que es la piedra angular del tratamiento médico. La TVM suele asociar estados protrombóticos, siendo de especial interés clínico los trastornos hematológicos (síndromes mieloproliferativos y mutaciones del gen JAK2). Por otro lado, la tasa de supervivencia a los 5 años es del 70-82%, y la mortalidad global precoz puede llegar hasta el 20-32% (AU)


Mesenteric vein thrombosis (MVT) is a rare condition that can present acutely, subacutely, or chronically. MVT can be isolated or within a splanchnic thrombosis (spleno-porto-mesenteric). Symptomatic cases usually present as nonspecific abdominal pain, with or without signs of intestinal ischemia, and the diagnosis is usually made by imaging test (abdominal CT or MRI) in patients with high clinical suspicion. An early clinical-surgical approach is recommended to screen those patients with warning signs and who benefit from an exploratory laparotomy in addition to anticoagulant treatment, which is the cornerstone of medical treatment. MVT is usually associated with prothrombotic states, with hematological disorders (myeloproliferative syndromes and/or JAK2 gene mutations) being of special clinical relevance. On the other hand, the 5-year survival rate is 70-82% and early overall 30-day mortality from MVT can reach 20-32% (AU)


Assuntos
Trombose Venosa/diagnóstico , Trombose Venosa/terapia , Veias Mesentéricas , Trombofilia , Isquemia , Anticoagulantes
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...